INBXInhibrx Biosciences Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $101.77 · now $101.77 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, INBX has typically landed between $74.00 and $155.89 — a range of −27.3% to +53.2% from the issuance price $101.77.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,503 overlapping 1 month windows · 2020-08-19 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($101.77) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where INBX has typically landed a month from the 2026-09-16 close of $101.77 — the range is history, not a prediction.

$74worst · -27.3%$155.89best · +53.2%
  • now $101.77 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $101.58 (-0.2%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $88.16–$114.99
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $74–$155.89
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,503 windows spanning 2020-08-19 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-05-29−59.7%−59.7%+0.0%
2024-05-24−57.8%−57.8%+2.4%
2024-05-28−57.7%−58.0%+1.8%
3 best
2025-10-23+185.6%+0.0%+195.9%
2025-10-22+166.3%−10.0%+166.3%
2020-11-17+142.1%+0.0%+142.1%

1,503 overlapping windows · 2020-08-19 – 2026-09-16 · not cherry-picked

Pending catalysts

  • May 2029 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (source, as of 2026-08-14)
  • July 2033 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~7 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
33%
−9.2%
n=6
Feb
0%
−8.8%
n=6
Mar
33%
−7.9%
n=6
Apr
50%
+11.1%
n=6
May
33%
−11.2%
n=6
Jun
50%
+1.8%
n=6
Jul
67%
+12.7%
n=6
Aug
100%
+15.4%
n=6
Sep
71%
+2.0%
n=7
Oct
67%
+37.3%
n=6
Nov
67%
+14.6%
n=6
Dec
67%
+14.6%
n=6

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$142$222026-09-15: 1 insider sale, $53K — MANHARD KIMBERLY2026-09-14: 1 insider sale, $55K — MANHARD KIMBERLY2026-09-11: 1 insider sale, $56K — MANHARD KIMBERLY2026-09-09: 1 insider sale, $58K — MANHARD KIMBERLY2026-09-08: 8 insider purchases, $3.5M — Lappe Mark, Kayyem Jon Faiz, FORSYTH DOUGLAS …2026-09-08: 1 insider sale, $58K — MANHARD KIMBERLY2025-10-07: 3 insider sales, $11.3M — VIKING GLOBAL INVESTORS LP …2025-10: 3 open-market sales, $11.3M2026-09: 8 open-market purchases, $3.5M2026-09: 5 open-market sales, $279K↑ buys↓ salesdirector MANHARD KIMBERLY — Sale on 2026-09-15, filed same daydirector MANHARD KIMBERLY — Sale on 2026-09-14, filed 1 day after the tradedirector MANHARD KIMBERLY — Sale on 2026-09-11, filed 4 days after the tradedirector MANHARD KIMBERLY — Sale on 2026-09-09, filed 1 day after the tradedirector Lappe Mark — Purchase on 2026-09-08, filed same daydirector Lappe Mark — Purchase on 2026-09-08, filed same daydirector Lappe Mark — Purchase on 2026-09-08, filed same daydirector Kayyem Jon Faiz — Purchase on 2026-09-08, filed same daydirector FORSYTH DOUGLAS — Purchase on 2026-09-08, filed same daydirector Lappe Mark — Purchase on 2026-09-08, filed same daydirector Lappe Mark — Purchase on 2026-09-08, filed same daydirector MANHARD KIMBERLY — Sale on 2026-09-08, filed 2 days after the tradedirector Lappe Mark — Purchase on 2026-09-08, filed same daytenPercentOwner VIKING GLOBAL INVESTORS LP — Sale on 2025-10-07, filed 2 days after the tradetenPercentOwner VIKING GLOBAL INVESTORS LP — Sale on 2025-10-07, filed 2 days after the tradetenPercentOwner VIKING GLOBAL INVESTORS LP — Sale on 2025-10-07, filed 2 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-09-15MANHARD KIMBERLYdirectorSale500 @ $105.05$53K−6.3% of holdingnot yet — horizon still opennot yet — horizon still open7,500Form 4 · filed same day
2026-09-14MANHARD KIMBERLYdirectorSale500 @ $110.26$55K−5.9% of holdingnot yet — horizon still opennot yet — horizon still open8,000Form 4 · filed 1 day after the trade
2026-09-11MANHARD KIMBERLYdirectorSale500 @ $111.78$56K−5.6% of holdingnot yet — horizon still opennot yet — horizon still open8,500Form 4 · filed 4 days after the trade
2026-09-09MANHARD KIMBERLYdirectorSale500 @ $115.80$58K−5.3% of holdingnot yet — horizon still opennot yet — horizon still open9,000Form 4 · filed 1 day after the trade
2026-09-08Lappe MarkdirectorPurchase9,681 @ $112.28$1.1M+1.3% of holdingnot yet — horizon still opennot yet — horizon still open730,548Form 4 · filed same day
2026-09-08Lappe MarkdirectorPurchase6,605 @ $100.64$665K+0.9% of holdingnot yet — horizon still opennot yet — horizon still open718,048Form 4 · filed same day
2026-09-08Lappe MarkdirectorPurchase5,895 @ $99.29$585K+0.8% of holdingnot yet — horizon still opennot yet — horizon still open711,443Form 4 · filed same day
2026-09-08Kayyem Jon FaizdirectorPurchase5,000 @ $113.52$568K+1.2% of holdingnot yet — horizon still opennot yet — horizon still open424,360Form 4 · filed same day
2026-09-08FORSYTH DOUGLASdirectorPurchase2,500 @ $114.65$287K+1.1% of holdingnot yet — horizon still opennot yet — horizon still open227,064Form 4 · filed same day
2026-09-08Lappe MarkdirectorPurchase1,219 @ $111.88$136K+0.2% of holdingnot yet — horizon still opennot yet — horizon still open720,867Form 4 · filed same day
2026-09-08Lappe MarkdirectorPurchase1,100 @ $107.12$118K+0.2% of holdingnot yet — horizon still opennot yet — horizon still open719,148Form 4 · filed same day
2026-09-08MANHARD KIMBERLYdirectorSale500 @ $115.14$58K−5.0% of holdingnot yet — horizon still opennot yet — horizon still open9,500Form 4 · filed 2 days after the trade
2026-09-08Lappe MarkdirectorPurchase500 @ $108.23$54K+0.1% of holdingnot yet — horizon still opennot yet — horizon still open719,648Form 4 · filed same day
2025-10-07VIKING GLOBAL INVESTORS LPtenPercentOwnerSale308,643 @ $32.25$10.0M−19.6% of holding+141.6%+122.6%1,267,823Form 4 · filed 2 days after the trade
2025-10-07VIKING GLOBAL INVESTORS LPtenPercentOwnerSale25,042 @ $32.25$808K−19.6% of holding+141.6%+122.6%102,864Form 4 · filed 2 days after the trade
2025-10-07VIKING GLOBAL INVESTORS LPtenPercentOwnerSale16,315 @ $32.25$526K−19.6% of holding+141.6%+122.6%67,018Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

15 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-03FORSYTH DOUGLASdirectorAward / grant15,00015,000Form 4
2026-06-03MANHARD KIMBERLYdirectorAward / grant15,00015,000Form 4
2026-06-03Kayyem Jon FaizdirectorAward / grant15,00015,000Form 4
2026-06-03Vuori Kristiina MDdirectorAward / grant15,00015,000Form 4
2026-04-24Matly DavidofficerAward / grant50,00050,000Form 4
2025-05-28MANHARD KIMBERLYdirectorAward / grant15,00015,000Form 4
2025-05-28Vuori Kristiina MDdirectorAward / grant15,00015,000Form 4
2025-05-28FORSYTH DOUGLASdirectorAward / grant15,00015,000Form 4
2025-05-28Kayyem Jon FaizdirectorAward / grant15,00015,000Form 4
2025-04-01Matly DavidofficerAward / grant50,00050,000Form 4
2025-04-01Deck KellyofficerAward / grant15,00015,000Form 4
2025-03-27Kayyem Jon FaizdirectorGift90,000419,360Form 4
2024-12-16Kayyem Jon FaizdirectorGift500,000509,360Form 4
2024-12-16Kayyem Jon FaizdirectorGift250,000250,000Form 4
2024-12-06Kayyem Jon FaizdirectorGift52,0001,009,360Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.